The White House is reviewing a new FDA user fee deal that would set prescription drug user fees for 2028 through 2032, according to sources cited in the report. The development adds another decision layer to the already politically sensitive FDA workload and resourcing discussion as the agency faces major throughput demands. Separately, FDA-related commentary at recent oncology meetings has emphasized the need to accelerate early-stage trials and restore structured feedback loops for developers, even amid leadership changes.